Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Endocr Relat Cancer. 2023 Sep 13;30(11):e220301. doi: 10.1530/ERC-22-0301

Table 4:

Clinical Efficacy

Parameter Outcome
Median Duration of Therapy with:
Temsirolimus
Bevacizumab
3.9 months
3.4 months
Median Progression-Free Survival 7.1 months (95% CI 4.6 – 8.7 months)
Objective Response Rate 2% (1 out of 48)
Stable Disease Rate 88% (42 out of 48)